Please assess the completion status of the following clinical trial:

Trial Title: Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provide written informed consent.~* Has a diagnosis of true or functional iron deficiency without anemia within 30 days of treatment on this protocol~  * Iron deficiency without anemia (normal Hgb \>/= 11.6 g/dL but ferritin \< 30 ng/mL)~ * Functional iron deficiency without anemia (ferritin \>30 ng/ml and iron saturation of \<50%)~* Has a clinical diagnosis of suspected epithelial ovarian cancer based on imaging studies, exam findings and laboratory values~* Participants must be planning to receive neoadjuvant chemotherapy for their cancer diagnosis (NACT is defined as chemotherapy prior to debulking surgery)~* Participants must be planning to undergo surgery for their cancer diagnosis~* Women of child-bearing potential (WOCBP) must have a negative serum pregnancy test within 7 days prior to administration of first dose of IV iron sucrose. WOCBP is defined as patients who retain their reproductive structures and are not menopausal (defined as \> age 50 with no menses for at least 1 year)~* Participants of reproductive potential must agree to use effective birth control during study participation. Effective birth control is defined as any FDA approved contraceptive method~Exclusion Criteria:~* Currently taken any form of oral or intravenous iron therapy. Patients must have discontinued iron therapy \> 30 days from study entry~* Current untreated or unstable heart disease~* History of iron induced hypersensitivity or allergy~* History of leukemia, lymphoma, or other myelodysplastic disorders~* Prior diagnosis of hemochromatosis or hemoglobinopathy (e.g. thalassemia)~* Any subject with immediate requirement for radiotherapy~* Concomitant enrollment in another clinical trial interfering with endpoints on this study~* Any medical condition which could compromise participation in the study according to the investigator's assessment~* Female patient who is pregnant or breast-feeding~* Patients unwilling or unable to comply with the protocol or unable to give informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IV Iron Sucrose (Type: EXPERIMENTAL): Four intravenous iron sucrose infusions prior to debulking surgery administered as four 200mg infusions, given no less than 7 days apart over a 30 day +/- 7 day period

Based on this trial design, predict the completion outcome and termination type (if applicable).